Business Development
Spin Offs
At Ospedale San Raffaele, we believe that pioneering research can drive real-world innovation. Our spin-offs are a testament to the institution’s commitment to transforming scientific discoveries into practical solutions that improve healthcare outcomes. By fostering the development of new companies, we aim to bridge the gap between research and industry, creating tangible value for patients, society, and the economy. The Business Development division plays a pivotal role in this process, evaluating the potential of research outcomes, supporting the creation of start-ups, and facilitating the relationship between researchers and investors, industrial partners and institutions, ensuring that innovations have the best opportunity to become viable products for patients with unmet needs. Join us in shaping the future of healthcare. Whether you are a researcher, venture capitalist, or corporate partner, we welcome the opportunity to explore innovative collaborations and bring groundbreaking solutions to life.
Contact: Michela Cristofolini
Business Development Division | businessdevelopment@hsr.it
OSR SPIN OFFs
GENENTA SCIENCE
Gene-edited cell therapy harnessing hematopoietic stem cells to provide durable and safe treatments for solid tumors. The technology exploits a subset of tumor-associated macrophages engineered to deliver an immunotherapeutic payload within tumors, where they can direct the natural immune responses towards malignant cells.
Latest News and Achievements:
March, 2025 https://ir.genenta.com/news-releases/news-release-details/genenta-announces-eu20-million-219m-financing-expand-pipeline October, 2024 Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
December, 2021 Genenta Closes Its Upsized Initial Public Offering of American Depository Shares
GENESPIRE
In vivo gene therapy platforms based on proprietary immune-shielded lentiviral vectors to treat metabolic disorders and hemophilia. This innovative platform, with application in many genetic diseases, promises to extend the reach of in vivo gene therapy, offering a one-time, off-the-shelf treatment for both adult and pediatric patients.
Latest News and Achievements:
September, 2024 Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic
May, 2024 Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting
NCHROMABIO
Therapeutic strategies based on proprietary engineered synthetic transcriptional factors (Epigenetic Silencer Factors) that ultimately inhibit cancerous oncogenes. Such solutions are intended for those solid tumor cases in which the radical removal is not possible and metastasizing or recurrence is highly probable (e.g. glioblastoma)
Latest News and Achievements:
December, 2024 https://www.nchromabio.com/news/chroma-medicine-and- nvelop-therapeutics-unite-to-form-nchroma-bio-securing-75- million-to-accelerate-genetic-medicines
November, 2021 Chroma Medicine acquires Epsilen Bio forming transatlantic pioneer in epigenetic editing
BIOREK
Innovative high-sensitivity and high-specificity molecular tests for the early diagnosis and the prognosis of renal carcinoma, based on the combined analysis of Single Nucleotide Polymorphisms (SNPs) and microRNAs in blood samples
Latest News and Achievements:
August, 2019 Biorek Secures Funds Involving Strategic Investors with Industry Expertise
REPRON THERAPEUTICS
Repron
Therapeutic strategies based on proprietary engineered synthetic transcriptional factors (Epigenetic Silencer Factors) that ultimately inhibit cancerous oncogenes. Such solutions are intended for those solid tumor cases in which the radical removal is not possible and metastasizing or recurrence is highly probable (e.g. glioblastoma)
Latest News and Achievements:
June, 2023 Repron Therapeutics raises €2 million round
PROUDLY SUPPORTED BY STRATEGIC INVESTORS
CDP Venture Capital Sgr, Fondo Nazionale Innovazione | Fondazione Telethon | EXTEND - National Technology Transfer Biotech Hub | XGEN Venture |INDACO - Venture Partner Sgr | Sofinnova Partners